The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CBIO | -20.94% | -96.07% | -47.66% | -21% |
| S&P | +15.06% | +95.03% | +14.29% | +12% |
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 83.9% |
| Gross Margin | -132.97% | 0.0% |
| Market Cap | $10.42M | -42.6% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 33 | 0.0% |
| Net Income | -$21.79M | -115.8% |
| EBITDA | -$21.03M | -103.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $152.65M | 581.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.43M | 0.0% |
| Short Term Debt | $0.21M | -53.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -45.29% | 45.4% |
| Return On Invested Capital | -206.72% | -135.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22.30M | -150.7% |
| Operating Free Cash Flow | -$22.16M | -149.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.96 | 3.02 | 4.01 | 3.09 | 391.53% |
| Price to Sales | 15196.95 | 19337.17 | 1815.87 | 1089.78 | - |
| Price to Tangible Book Value | 95.79 | 141.14 | 254.85 | 3.09 | -95.08% |
| Enterprise Value to EBITDA | 0.57 | -1.02 | -3.31 | 4.03 | 1003.45% |
| Return on Equity | -137.2% | -173.2% | -182.7% | -51.7% | -50.53% |
| Total Debt | $0.26M | $0.07M | $0.00M | $1.64M | 266.33% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
